Pharmaceutical

EC approves Pfizer’s Talzenna combo for prostate cancer treatment

The EC has granted approval for Pfizer’s Talzenna (talazoparib) to treat adults with metastatic castration-resistant prostate cancer (mCRPC).

Jan 9, 2024 - 18:00
EC approves Pfizer’s Talzenna combo for prostate cancer treatment
The EC has granted approval for Pfizer’s Talzenna (talazoparib) to treat adults with metastatic castration-resistant prostate cancer (mCRPC).
Read the original article

Tags:

Previous Article

BIOS Health to launch precision medicine centre in California, US

Next Article

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ZyVersa Therapeutics inches closer to European patent approval for VAR 200

ZyVersa Therapeutics inches closer to European patent a...

Jun 7, 2023

ARTHEx Biotech raises funds to advance DM1 therapy to clinical trial

ARTHEx Biotech raises funds to advance DM1 therapy to c...

May 4, 2023

STAT+: DOJ, FTC primed for more aggressive scrutiny of health care mergers

STAT+: DOJ, FTC primed for more aggressive scrutiny of ...

Jul 20, 2023